KDM1A and breast neoplasm: Verigos et al. [53] treated the aggressive types of breast tumor cells, MCF-7 and MDA-MB-468, that have developed therapy resistance with LSD1 inhibitor, GSK-LSD1, and gave them increasing doses of doxorubicin (0–5 μM).